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ABSTRACT 8 
An isotope dilution mass spectrometry (IDMS) method for the determination of selected 9 
endogenous anabolic androgenic steroids (EAAS) in urine by UHPLC-MS/MS has been 10 
developed using the isotope pattern deconvolution (IPD) mathematical tool. The method has 11 
been successfully validated for testosterone, epitestosterone, androsterone and 12 
etiocholanolone, employing their respective deuterated analogs using two certified reference 13 
materials (CRM). Accuracy was evaluated as recovery of the certified values and ranged from 14 
75% to 108%. Precision was assessed in intraday (n=5) and interday (n=4) experiments, with 15 
RSDs below 5% and 10% respectively. The method was also found suitable for real urine 16 
samples, with limits of detection (LOD) and quantification (LOQ) below the normal urinary 17 
levels. The developed method meets the requirements established by the World Anti-Doping 18 
Agency for the selected steroids for Athlete Biological Passport (ABP) measurements, except in 19 
the case of androsterone, which is currently under study. 20 
 21 
INTRODUCTION 22 
Misuse of steroids is nowadays a significant social issue. Apart from doping in sports, 23 
endogenous anabolic androgenic steroids (EAAS) use has become a problem of public health 24 
[1]. Regarding substances prohibited in sports, over the years consensus has been achieved 25 
about which steroidal markers must be controlled as an additional part of the World Anti-26 
Doping Agency (WADA) Athlete Biological Passport (ABP), the steroidal module [2]. 27 
Testosterone (T), epitestosterone (E), androsterone (A), etiocholanolone (Etio), 5α-androstane-28 
3α,17β-diol (5αAdiol), 5β-androstane-3α,17β-diol (5βAdiol) and the ratios T/E, A/T, A/Etio, 29 
5αAdiol/5βAdiol, 5βAdiol/E are the parameters of choice. An abnormal steroidal or 30 
longitudinal profiles may constitute a suspicion of doping, thus, reliable analytical methods are 31 
needed to assess the concentration of those EAAS. Moreover, clear verification of exogenous 32 
administration of EAAS is still a challenge. The general workflow includes an initial screening 33 
method followed by a confirmation if adverse results are found. However, in spite of WADA 34 
efforts, a completely standardized methodology has not been established yet, neither by the 35 
mass detector (Q or QqQ), nor by the sample treatment method used in that initial screening 36 
step [3]. Although the accepted WADA quantification method for EAA determination in urine is 37 
GC/MS [2], among current instrumental techniques in drug testing, UHPLC-MS/MS is mainly 38 
used due to its high throughput, chromatographic performance and sensitivity [4-6]. 39 
On the other hand, ESI, the most employed ionisation source in LC-MS instrumental 40 
techniques can suffer severe matrix effect problems, mainly related with ion suppression or 41 
enhancement [7-9]. The use of isotope labelled internal standards (ILIS) is widely recognized as 42 
the best way to overcome matrix effect problems. Thus, quantification through isotope 43 
dilution mass spectrometry (IDMS) works out the issues related with signal alteration [10,11]. 44 
A recently developed IDMS method of quantification, isotope pattern deconvolution (IPD), 45 
does not rely on the construction of any calibration graph. IPD involve the artificial alteration 46 
of the natural isotopomer abundances of a compound in a sample by the addition of a known 47 
amount of a labelled analogue. The isotopic composition of the blend is a linear combination 48 
of two isotope patterns: that of the natural abundance compound and the isotope pattern of 49 
the labelled analogue. The separate contribution of each ‘isotope pattern’ to the whole mass 50 
spectrum can be calculated by multiple linear regression and provides the molar fractions of 51 
both labelled and unlabelled compound in the sample. [12-14]. This method has been 52 
satisfactorily tested for rapid quantifications in different complex matrices, such as food and 53 
environmental samples [15-18]. IDMS together with IPD can be considered a reliable (precise 54 
and accurate) methodology, free of matrix effect and fast, providing one result per injection. 55 
However, except for a recent paper related with testosterone determination in urine [19], IPD 56 
has never been applied to steroid determination. 57 
In this work, an UHPLC-MS/MS method, based in IDMS and IPD quantification approach, is 58 
developed and validated for the determination of selected EAAS in human urine. T, E, A and Etio 59 
were selected among the EAAS included in the ABP, excluding the diols due to the known 60 
ionization difficulties by ESI of hydroxyandrostane compounds [20]. Accuracy and precision has 61 
been checked for the selected compounds, as well as ratios, through the analysis of NMIA 62 
MX002 and MX005 freeze dried human urine CRMs. 63 
 64 
EXPERIMENTAL 65 
Reagents and materials 66 
Testosterone (T, purity 99%) and etiocholanolone (Etio, purity 98%) were provided by Sigma-67 
Aldrich (Saint Louis, MO, USA), epitestosterone (E, purity 96.1%) was provided by LGC 68 
Standards (Luckenwalde, Germany) and androsterone VETRANAL® (A, purity 98.2%) by Sigma-69 
Aldrich (Seelze, Germany). D3-Testosterone (d3-T, d3≈91%), d3-epitestosterone (d3-E, 70 
d3≈94%), d4-androsterone (d4-A, d4≈81%), d5-etiocholanolone (d5-Etio, d5≈92%) and 71 
certified reference materials (CRMs) NMIA MX002 and MX005 were all purchased to NMI 72 
Australia (North Ryde, NSW, Australia). Molecular structure of the selected EAAS are shown in 73 
Figure 1. 74 
Methanol (HPLC quality), acetonitrile (HPLC quality) and methyl tert-butyl ether (MTBE, GC 75 
quality) were provided by Scharlau (Barcelona, Spain). For the sample hydrolysis, β-76 
glucuronidase from E. coli K12 provided by Roche (Indianapolis, IN) was employed. A 1 M 77 
phosphate buffer was prepared by dissolving the proper amount of (NH4)2HPO4 (Merck, 78 
Darmstadt, Germany) in Milli-Q water and adjusted to pH=7 with HCl 37% from Scharlau 79 
(Barcelona, Spain). Also, a NaHCO3/Na2CO3 (1:2, w/w) (Sigma-Aldrich Co., Madrid, Spain) solid 80 
buffer was prepared. Formic acid (LC additive quality) and a 500 mM solution of NH4COOH 81 
(Scharlau, Barcelona, Spain) in methanol HPLC were used as modifiers for mobile phases. 82 
 83 
 84 
 85 
Figure 1. Molecular structure of the selected endogenous steroids. Location of D atoms are 86 
displayed for the labeled compounds. 87 
 88 
Individual stock solutions were prepared with 500 µg/mL of T, 200 µg/mL of E, 500 µg/mL of A, 89 
500 µg/mL of Etio and 100 µg/mL of each deuterated analog (d3-T, d3-E, d4-A and d5-Etio) by 90 
dissolving the proper amounts of solid standards in methanol. Then, 10 µg/mL working 91 
solutions of each compounds were prepared by dilution of stock solutions with methanol. A 92 
mix of labelled compounds was prepared in MeOH containing 1 µg/mL of d3-T and d3-E and 25 93 
µg/mL of d4-A and d5-Etio. All standard solutions were stored in amber glass bottles at -20ºC. 94 
CRMs were reconstituted following the procedure indicated by the manufacturer and stored in 95 
a refrigerator until use. 96 
Ultrapure water was obtained from a Milli-Q gradient A10 from Millipore (Bedford, MA, USA). 97 
 98 
Instrumentation 99 
Characterization and determination of analytes were performed on an Acquity UPLC system 100 
equipped with binary solvent and sample managers from Waters Corp. (Milford, MA, USA), 101 
coupled to a TQD quadrupole-hexapole-quadrupole tandem mass spectrometer and a Z-spray-102 
electrospray interface (Waters Corp.). Chromatographic separation was achieved at 55ºC on an 103 
Acquity UPLC BEH C18 column (1.7 µm, 2.1 mm x 100 mm, Waters Corp.) at 0.3 mL/min flow 104 
rate and 10 µL injection volume. Mobile phases consisted in H2O/ACN (95/5, v/v) as phase A 105 
and H2O/ACN (5/95, v/v) as phase B, both containing 0.01% of formic acid and 0.1 mM of 106 
NH4COOH as modifiers. The gradient applied was: 10% B (0-1 min), linear increase to 50% B in 107 
4.3 min, 50% B (5.3-9 min), 95% B (9.5-10.5 min), 10% B (11-13 min). 108 
Ionization was performed at 120ºC desolvation temperature and 350ºC source temperature, 109 
while cone gas and desolvation flows were set at 80 and 800 L/h respectively. 3.5 kV capillary 110 
voltage was applied in positive mode. Multiple reaction monitoring (MRM) conditions and 111 
retention times are listed in Table 1. 112 
Drying and nebulizing gas was N2 from a nitrogen generator N2 LC-MS adapted for LC-MS 113 
analyzers (Claind, Teknokroma, Barcelona, Spain). Collision cell was kept at approximately 5 x 114 
10-3 mbar of argon 99.995% provided by Praxair (Madrid, Spain). Dwell time was set to 0.1 s 115 
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per scan for all quantification measurements. Analytical data was processed using Masslynx 116 
v4.1 (Waters) and homemade Excel spreadsheets (Microsoft Office). 117 
 118 
 119 
Table 1. Experimental conditions of the LC-(ESI)-MS/MS for natural and labeled steroids 120 
Compound 
Ret. Time 
(min) 
Precursor ion 
Cone voltage 
(V) 
Collision 
voltage (V) 
MRM 
transitions* 
T 6.43 [M+H]+ 35 25 
289.2 > 96.9 
290.2 > 96.9 
289.2 > 109.1 
E 7.06 [M+H]+ 35 25 
289.2 > 96.9 
290.2 > 96.9 
289.2 > 109.1 
A 8.29 [M+NH4]+ 35 10 
308.3 > 273.1 
309.3 > 274.1 
308.3 > 291.1 
Etio 8.05 [M+NH4]+ 35 10 
308.3 > 291.1 
309.3 > 292.1 
308.3 > 273.1 
d3-T 6.40 [M+H]+ 35 25 
292.2 > 96.9 
293.2 > 96.9 
292.2 > 109.1 
d3-E 7.03 [M+H]+ 35 25 
292.2 > 96.9 
293.2 > 96.9 
292.2 > 109.1 
d4-A 8.24 [M+NH4]+ 35 10 
312.3 > 277.1 
313.3 > 278.1 
312.3 > 295.1 
d5-Etio 8.00 [M+NH4]+ 35 10 
313.3 > 296.1 
314.3 > 297.1 
313.3 > 278.1 
*In bold: MRM transitions employed for IPD quantification. 121 
 122 
Sample treatment 123 
A previously developed and widely used sample treatment method based on WADA guidelines 124 
[2] has been directly applied. 25 µL of labelled mix was added into 2.5 mL of sample in clean 15 125 
mL-glass tubes followed by 1 mL of 1 M phosphate buffer (pH=7). Hydrolysis was performed by 126 
adding 30 µL of β-glucuronidase solution and incubated in a water bath at 55 ± 2 ºC for 1 h. 127 
Next, approximately 200 mg of NaHCO3/Na2CO3 (1:2, w/w) solid buffer were added to the tube 128 
and stirred until total dissolution of the solid. Liquid-liquid extraction was carried out by adding 129 
6 mL of MTBE, stirring in a vortex for 1 min and centrifuging at 3500 rpm for 5 min. Then, the 130 
upper organic phase was carefully transferred to clean glass tubes using disposable Pasteur 131 
pipettes, avoiding transferring any aqueous phase. MTBE was eliminated by evaporation in a 132 
MiVac at 40ºC for 20 min, the residue was redissolved in 300 µL of MeOH/H2O (1:1, v/v) and 133 
transferred to LC vials. 134 
 135 
 136 
Method Validation 137 
Accuracy 138 
Accuracy was validated by recovery experiments applying the method to two CRMs with 139 
different steroid concentrations and ratios, NMIA MX002 and NMIA MX005 freeze dried 140 
human urine. The method was regarded as accurate if the recovery was between 70% and 141 
110%. 142 
Precision 143 
Using the same CRMs, intraday and interday precisions were validated. Intraday repeatability 144 
was assessed performing the analysis of five replicates. Interday reproducibility was obtained 145 
by the application of the method to four replicates in four consecutive weeks. 146 
In order to assess precision in terms of WADA guidelines [2], total combined uncertainty, uc, 147 
was also calculated according to WADA technical document TD2014DL [21] and Nordtest 148 
Guide [22]. A detailed explanation of the measurement uncertainty determination, using T as 149 
model compound in urine, is explained elsewhere [19]. The combined uncertainty for the 150 
ratios was assessed taking into account also the general propagation equation [23] to calculate 151 
the uncertainty associated to the reference material. A detailed explanation is shown in the 152 
supplementary information.  153 
LOD and LOQ 154 
A rough estimation of detection and quantification limits were conducted using the signal to 155 
noise ratio obtained in a real life sample. To this end, 9 urine samples from healthy female 156 
volunteers were collected and analyzed in order to get samples with low concentration of 157 
EAAS. Limits of quantification (LOQ) and detection (LOD) of the method were estimated as S/N 158 
equal to 10 and 3, respectively, in the lowest concentrated sample. 159 
 160 
Quantification by isotope pattern deconvolution (IPD) 161 
Isotope pattern deconvolution is a mathematical tool based on multiple linear regressions that 162 
provides the molar fractions of natural and labelled analytes in the spiked sample. The addition 163 
of the labelled analog alters the natural isotopic distribution of abundances  	  due to the 164 
overlap of the labelled isotopic distribution 
	. Hence, the deconvolution of the measured 165 
distribution in the mix 	  is performed by solving the multiple linear regression in matrix 166 
notation: 167 
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Where the error vector  is the minimized parameter in the regression to solve the system 169 
and to obtain the molar fractions of natural and labelled analytes (  and  
 respectively). 170 
This can be easily achieved with the LINEST function in Microsoft Excel or any spreadsheet 171 
software. Then, since the amount of labelled compound !
 is known, the amount of natural 172 
compound in the sample ! is readily calculated as follows: 173 ! = !
   
  174 
In contrast with commonly used analytical methodologies, IPD does not need methodological 175 
calibration and a concentration value is obtained from a single injection of the spiked sample. 176 
However, an extensive characterization of natural and labelled compounds is required to 177 
construct the calculation matrix, including isotopomer abundance distributions and exact 178 
concentration of labelled standard solutions (determined by reverse isotope dilution). If the 179 
individual isotopomer distribution is theoretically calculated, extent of labeling and spectral 180 
purity must be also characterized. Description of the general IPD methodology as well as 181 
examples of characterization of standards can be consulted in the literature [12,24]. In the 182 
present work, isotopomer abundances corresponding to the selected transitions for natural 183 
and labeled compounds have been experimentally obtained according to the method reported 184 
in previous works [19]. 185 
 186 
RESULTS AND DISCUSSION 187 
Optimization of LC conditions 188 
In a first approach, gradient conditions using methanol and water both containing 0.01% 189 
HCOOH/1mM NH4COOH as mobile phases were tested, as employed for testosterone 190 
determination in previous works [19]. However, due to the similarity between A and Etio 191 
(5α/5β-position isomers of one H), separation could not be accomplished even with long run 192 
times. Therefore, acetonitrile (ACN) was tested as mobile phase on the basis of the 193 
chromatographic conditions used by Hauser et al. [25], which consisted in water/ACN (95/5, 194 
v/v) (Eluent A) and water/ACN (5/95, v/v) (Eluent B), both containing HCOOH and NH4COOH. 195 
Different modifier concentrations were tested and 0.01% HCOOH plus 0.1 mM NH4COOH 196 
provided the optimal sensitivity and peak shape. 197 
Optimization of A/Etio separation was performed starting from isocratic conditions at different 198 
%B (10, 20 and 30%) to ensure that separation was possible with a C18 column. Once 199 
separation was observed using 30% Eluent B, peak shape and time analysis were tried to be 200 
improved by performing a gradient prior to an isocratic step. Thus, gradients of the same slope 201 
were tested starting from 0% or 10% Eluent B and arriving up to 30, 40 and 50% Eluent B, 202 
followed by the isocratic step. Separation of the A/Etio pair was achieved in all six 203 
experiments, but lower isocratic and initial % of Eluent B produced longer run times and 204 
decreased sensitivity due to peak broadening. Thus, starting conditions were set at 10 % 205 
eluent B, followed by a gradient up to 50% Eluent B in 4.3min and an isocratic step until 9 min. 206 
(Figure 2) 207 
 208 
Characterization of analytes 209 
Characterization of natural (T, E, A, Etio) and labelled compounds (d3-T, d3-E, d4-A, d5-Etio) 210 
consisted in the determination of the experimental isotopic distribution of abundances and 211 
exact concentration of labelled standard solutions. 212 
Experimental abundances were measured by injecting (n=5) individual 500 ng/mL of T, E, d3-T 213 
and d3-E, and 5 µg/mL of A, Etio, d4-A and d5-Etio in MeOH/H2O (1:1, v/v). MRM transitions 214 
were selected on the basis of theoretical fragmentation calculations by IsoPatrn software [26], 215 
selecting the 10-12 most abundant transitions. 216 
 217 
 218 
 219 
Figure 2. Chromatographic optimization using gradients of the same slope from 10% Eluent B 220 
at 1 min to A) 30% at 3.2 min, B) 40% at 4.25 min and C) 50% at 5.3 min, followed by an 221 
isocratic step (see text). All three injections correspond to a standard with 500 ng/mL T and E 222 
and 1.0 µg/mL A and Etio in MeOH/H2O (1:1, v/v). 223 
 224 
 225 
Finally, concentrations of labelled 100 µg/mL standard solutions were checked by reverse 226 
isotope dilution (RID). That is, quantification of labelled compound spiking the standard 227 
solution with an accurately prepared natural standard solution using IPD [27]. Results obtained 228 
by RID were: (100 ± 4) µg/mL for d3-T, (105.8 ± 1.1) µg/mL for d3-E, (98.2 ± 1.1) µg/mL for d4-A 229 
and (112.7 ± 1.9) µg/mL for d5-Etio. 230 
 231 
Method validation 232 
Accuracy assessment was carried out by applying the developed IPD methodology to 2 233 
certified reference materials (CRM) from NMI Australia: NMIA MX002 and NMIA MX005. 234 
Recovery, calculated as the percentage ratio between the found and the certified 235 
concentration value, is shown in tables 2 and 3. It is worth noting the high accuracy of the 236 
method for T, E and Etio, with recovery values between 95% and 108% in all experiments. 237 
However, results for A were lower than expected, between 75% and 79%, which may be 238 
caused by insufficient hydrolysis time and/or temperature. Though, interference of matrix 239 
components with d4-A mass spectrum is being also considered since an abnormally high 240 
response in labelled transition measurements produces lower quantifications by IPD. All these 241 
possibilities are currently under study. 242 
 243 
 244 
Table 2. Validation parameters, accuracy and precision, obtained for NMIA MX002 CRM. 245 
NMIA MX002 
Compound 
Certified 
value1 
Intra-day repeatability (n=5) Inter-day reproducibility (n=4) 
Concentration1 Accuracy2 Concentration1 Accuracy2 
T 16.6 ± 0.65 16.3 ± 0.3 (1.8%) 98% 15.9 ± 0.4 (2.4%) 96% 
E 18.3 ± 1.3 19.7 ± 0.3 (1.8%) 108% 19.0 ± 0.5 (3%) 104% 
A 1262 ± 39 963 ± 14 (1.4%) 76% 993 ± 81 (8%) 79% 
Etio 814 ± 36 840 ± 15 (1.8%) 103% 804 ± 41 (5%) 99% 
1 Expressed as Mean ± SD (%RSD) ng/mL 246 
2 As % recovery respect to the certified value 247 
 248 
Table 3. Validation parameters, accuracy and precision, obtained for NMIA MX005 CRM. 249 
NMIA MX005 
Compound 
Certified 
value1,3 
Intra-day repeatability (n=5) Inter-day reproducibility (n=4) 
Concentration1 Accuracy2 Concentration1 Accuracy2 
T 40.2 ± 1.8 37.3 ± 0.8 (2.0%) 93% 38.0 ± 0.7 (1.8%) 95% 
E 10.74 ± 0.59 11.3 ± 0.3 (3%) 105% 11.0 ± 0.3 (3%) 102% 
A 1184 ± 35 886 ± 40 (5%) 75% 890 ± 80 (9%) 75% 
Etio 1290 ± 41 1229 ± 30 (2.4%) 95% 1246 ± 55 (4%) 97% 
1 Expressed as Mean ± SD (%RSD) ng/mL 250 
2 As % recovery respect to the certified value 251 
3 Corrected as indicated in the manufacturer’s instructions (correction factor=0.9977), since 252 
the weighted water after reconstitution was 20.0461g 253 
 254 
 255 
Intra-day repeatability (n=5) and inter-day reproducibility (n=4) were assessed for both CRMs. 256 
Results in terms of repeatability and reproducibility showed RSD values below 5% and 10%, 257 
respectively, in all cases (Tables 2 and 3). A shows the highest %RSD that should be related 258 
with the poorer recovery. Despite that, the developed method is characterised by a high 259 
precision. 260 
In order to assess the method combined uncertainty, Nordtest calculations [22] were applied 261 
using the available data to obtain combined uncertainty for the determination of the four 262 
analytes (Table 4), plus the uncertainty of T/E, A/T and A/Etio ratios (Table 5). Total combined 263 
uncertainty, uc, allows the comparison with the WADA requirements for a quantification 264 
method [2]. 265 
Since the obtained A concentrations differed from the certified values, its uncertainty derived 266 
from the bias (u(bias) around 23%) was found to be higher than the rest (u(bias) between 3.2% 267 
and 5.5%). Therefore, combined uncertainties of A, A/T and A/Etio determinations were worse 268 
than the rest of analytes and ratios. Lower uncertainty values for A and A ratios are expected 269 
once the aforementioned recovery problems are solved. 270 
Regarding T, E and Etio, uc was about 6% or lower in all cases. Taking into account that certified 271 
concentrations in the CRMs (Tables 2 and 3) are >5 ng/mL for T and E, and above five times the 272 
method LOQ for A and Etio (Table 6), the concentration uncertainty of the method was far 273 
lower than the limit of 20% set by the WADA for those three analytes [2].  274 
Regarding T/E, the method uc was 9%, also below the WADA requirements of 15%, and far 275 
lower than the observed longitudinal individual variation in male urine. In a recent paper [28] 276 
coefficients of variation of 30% and 46% for longitudinal T/E values where found when one or 277 
various laboratories were involved respectively. As might be expected, those values contain 278 
not only the individual variation but the method precision itself. Thus, a method with lower 279 
measurement uncertainty would help in assessing the actual variability in longitudinal steroidal 280 
profile for a given individual. 281 
 282 
Table 4. Combined uncertainty, uc, for the four selected EAAS. 283 
Compound u(bias) Rw uc1 
T 5,5% 1,8% 5,8% 
E 4,3% 1,8% 4,7% 
A 23,2% 10,3% 25,4% 
Etio 3,2% 5,2% 6,1% 
1 uc calculated as the square root of the sum of the squares of interday reproducibility (Rw, 284 
random uncertainty) and u(bias), the uncertainty associated to any source of bias including 285 
that associated to CRMs [19,22]  286 
 287 
Table 5. Combined uncertainty, uc, for the selected ratios. 288 
Ratio u(bias) Rw uc1 
T/E 8,6% 2,7% 9,0% 
A/T 19,2% 8,8% 21,1% 
A/Etio 21,5% 5,6% 22,2% 
1 uc calculated as the square root of the sum of the squares of interday reproducibility (Rw, 289 
random uncertainty) and u(bias), the uncertainty associated to any source of bias including 290 
that associated to CRMs [22,23]  291 
 292 
Finally, limits of quantification (LOQ) and detection (LOD) of the method were roughly 293 
estimated as S/N equal to 10 and 3, respectively. To this end, the lowest concentrated sample 294 
among 9 healthy female volunteers were selected (see experimental section). Lowest values 295 
found within the samples for each analyte are shown in Table 6 along with their corresponding 296 
LOQ and LOD. 297 
Table 6. Concentration of steroids in the selected urine sample and calculated LOD and LOQ. 298 
Compound Sample ID1 Mean ± SD (%RSD) ng/mL LOD (ng/mL) 2 LOQ (ng/mL) 3 
T 4 0.520 ± 0.024 (5%) 0.2 0.7 
E 8 1.48 ± 0.09 (6%) 0.5 1.7 
A 8 301 ± 5 (1.8%) 7.3 24.5 
Etio 8 587 ± 15 (3%) 28.6 95.4 
1 Results for all 9 samples can be consulted in the Supplementary Information (Table S.4) 299 
2 S/N = 3 300 
3 S/N = 10 301 
 302 
A brief summary of figures of merit of the here developed method reveals that accuracy (75-303 
108% recovery) compares well with already published results, while precision shows equal CV 304 
values or better, specifically for T and E and inter-day precision study. On the other hand, as 305 
IPD methodology does not require the use of calibration curves and derivatization steps are 306 
ommitted in LC, the application of IPD quantification makes the method fast and reliable. 307 
Table S.5 in supplementary information shows validation results from some selected methods 308 
including those of the present work. 309 
 310 
 311 
CONCLUSIONS 312 
In this work, an IDMS method for UHPLC-MS/MS has been proved suitable for EAAS 313 
determination in human urine. Isotope pattern deconvolution (IPD) was employed as 314 
mathematical tool to perform the quantification of testosterone, epitestosterone, 315 
androsterone and etiocholanolone, using deuterium-labelled analogs for that purpose. 316 
The high similarity of molecular structure between A and Etio required of an extensive 317 
optimization of the chromatographic separation using an acetonitrile gradient. 318 
The method was successfully validated with its application to two certified reference materials 319 
in terms of intraday repeatability and interday reproducibility with low relative standard 320 
deviations (%RSD < 10%) in both experiments, as well as in terms of trueness or recovery 321 
respect the certified concentration values (between 75% and 110%). 322 
In addition, LODs and LOQs of the method were estimated in real life, low concentrated, 323 
female urine samples. All limits were found suitable for the determination of EAAS since they 324 
fell below the normal range of concentration in adults. 325 
Combined standard uncertainty for T, E, Etio and T/E were below the WADA required limits for 326 
a method to be useful in doping suspicion. Moreover, uc(T/E) is well below the observed 327 
coefficients of variation for individual longitudinal profiles, thus allowing to improve future 328 
variability assessment studies. Regarding the lower performance of A and their ratios current 329 
studies are being conducted to improve the associated uncertainty. 330 
Therefore, the present IPD method by LC-MS/MS is highlighted as a robust, exact and precise, 331 
and constitutes a potential alternative approach for endogenous steroid analysis and a capable 332 
alternative to traditional GC- and calibration-based quantifications. Since the ionization source 333 
used in this work, ESI, is not suited for the determination of 5αAdiol and 5βAdiol, future works 334 
will be focused on their inclusion in the method as alternate forms. In this sense, the direct 335 
determination of glucuronide conjugates seems to be a good alternative to continue 336 
developing IPD as a reliable approach in EAAS determination. 337 
 338 
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